# Predicting drug sensitivity using (epi)genomic marks

Elysia Chou, Keefer Chern, Alexander Chang May 1, 2019

#### Introduction

Cancer cell lines are widely used to study drug efficacy in vitro.

#### Aims:

Predictively model drug efficacy using elastic net regression with either

1. Epigenomic features (histone modifications)

or

2. Genomic features (gene expression)



The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

Jordi Barretina, Giordano Caponigro [...] Levi A. Garraway <sup>™</sup>

#### Paper's approach:

- Trained on all of the data
- Uses genomic data (not all public)

#### Our approach:

- Train on 80% of the data
- Explore relationship between (epi-) genomic profiles and drug sensitivity

### **Data**

#### **Features**

- Global Chromatin Profiling
- Gene Expression


#### Labels

Drug sensitivity for
 PD-0325901 (MEK inhibitor)






#### Drug Response for a cancer cell line




Drug concentration (in  $\mu M$ )

# Global Chromatin Profiling Analysis


# Post-translational histone modifications





Histone acetylations

### Global Chromatin Profiling (GCP) Data



### 42 histone modifications



### Resolve Missing Values

- If # NaNs ≤ 30: impute missing values with mean of the column
- Columns removed if # NaNs > 30
- Features remaining: 39
- Labels remaining: 3

Column	Column name	# of NaNs
2	H3K4me0	1
5	H3K4ac1	40
20	H3K18ac0K23ub1	162
34	H3K27ac1K36me0	3
35	H3K27ac1K36me1	15
36	H3K27ac1K36me2	5
37	H3K27ac1K36me3	1
40	H3K56me1	162
42	H3K79me1	1
43	H3K79me2	2

### Method: Elastic Net Regression


- Linear regression with L1 and L2 regularization
- Supposed to be better at dealing with situations with correlations between parameters
- Loss function:

$$L_{enet}(\hat{eta}) = rac{\sum_{i=1}^{n} (y_i - x_i' \hat{eta})^2}{2n} + \lambda (rac{1-lpha}{2} \sum_{j=1}^{m} \hat{eta}_j^2 + lpha \sum_{j=1}^{m} |\hat{eta}_j|),$$

- $\alpha$  = mixing parameter (lower  $\rightarrow$  less L1)
- $\lambda$  = regularization parameter (0 = no regularization)

## Hyperparameter Tuning for Elastic Net Regression

- 80/20 train/test split
- Determine optimal  $\alpha$  and  $\lambda$  for our model using 10-fold cross-validation on training set
- MSE and R<sup>2</sup>



### **Results**

From hyperparameter tuning

	Lambda	Alpha	MSE Test	MSE Train	R2
84	0.1	1.00	2.086050	2.020410	0.016703
83	0.1	0.95	2.087535	2.018359	0.017698
82	0.1	0.90	2.090324	2.015804	0.018938
81	0.1	0.85	2.093176	2.013152	0.020227
80	0.1	0.80	2.096937	2.010303	0.021611

#### Activity Area

	Lambda	Alpha	MSE Test	MSE Train	R2
101	0.3	1.00	12.993113	12.524075	0.021803
84	0.1	1.00	13.019230	11.893680	0.071047
83	0.1	0.95	13.025692	11.879694	0.072139
100	0.3	0.95	13.032337	12.536065	0.020867
82	0.1	0.90	13.036028	11.866107	0.073199

IC 50

A\_max

# Linear regression on individual features showed no significant correlation

 Multiple hypothesis correction to reduce false discovery rate using Benjamini-Hochberg


```
[ ] # Multiple Hypothesis IC50
    results_d, peas = fdr_test(X_mean_ni, Y[:,0])
    print(np.sum(results_d))

[ ] # Multiple Hypothesis AMax
    results_d, peas = fdr_test(X_mean_ni, Y[:,1])
    print(np.sum(results_d))

[ ] # Multiple Hypothesis ActArea
    results_d, peas = fdr_test(X_mean_ni, Y[:,2])
    print(np.sum(results_d))


[ ] # O
```


## Heatmap shows little correlation between 39 features



## PCA shows no distinction between features and data







Absolute Pearson correlation between PCs and features was < 0.1

### Reasoning our results

- 1. May still have correlation
  - a. We did not have enough features (39) for the patterns/relations to be captured
  - b. Since this is mass spectrometry downstream data, there could have been too many confounding factors that muffled out patterns for a signalling pathway.
- There could be no correlation.

# Gene Expression Analysis



### **Resolve Missing Values**

- Missing values only present in EC50, so we decided not to use it as a label. (134 missing values)
- No missing values in gene expression data

Description	LOC100009676	AKT3	MED6	NR2E3	NAALAD2	CDKN2B-AS1	LOC100049716
1321N1_CENTRAL_NERVOUS_SYSTEM	6.086570	8.109723	9.773439	3.738350	3.531070	3.973706	4.200785
22RV1_PROSTATE	6.079415	4.521625	8.845639	3.768181	4.044822	4.151676	5.136966
42MGBA_CENTRAL_NERVOUS_SYSTEM	5.373842	6.631749	10.001350	3.610522	4.242035	3.859894	4.175044
5637_URINARY_TRACT	5.979812	6.595651	9.663415	4.040661	4.159523	4.099417	4.284730
639V_URINARY_TRACT	6.364203	6.172691	9.480367	3.807020	3.699464	4.412172	4.795315
697_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE	5.489103	6.056583	9.505763	3.922257	3.614177	4.388497	4.990959

### Method: Elastic Net Regression

- Linear regression with L1 and L2 regularization
- Supposed to be better at dealing with situations with correlations between parameters
- Loss function:

$$L_{enet}(\hat{eta}) = rac{\sum_{i=1}^{n} (y_i - x_i' \hat{eta})^2}{2n} + \lambda (rac{1-lpha}{2} \sum_{j=1}^{m} \hat{eta}_j^2 + lpha \sum_{j=1}^{m} |\hat{eta}_j|),$$

- $\alpha$  = mixing parameter (lower  $\rightarrow$  less L1)
- $\lambda$  = regularization parameter (0 = no regularization)

### **Results**

	Fı	rom h	vperpa	ırameter	tunina	65	0.03	0.90	0.160146	0.041204	0.838838	3
							0.03	0.85	0.161186	0.037957	0.851542	2
							0.03	0.80	0.162848	0.034817	0.86382	1
	Lambda	Alpha	MSE Val	MSE Train	R2				Activity Are	ea e		
101	0.3	1.00	8.542118	4.143462	0.675630		Lambda	Alpha	MSE Val	MSE Train	R2	
100	0.3	0.95	8.604842	3.955840	0.690318	135	3.0	1.00	535.081636	317.188125	0.630173	
99	0.3	0.90	8.668106	3.755339	0.706022	118	1.0	1.00	550.770765	68.105051	0.920636	]
98	0.3	0.85	8.760968	3.548933	3.548933 0.722189 3.360213 0.736963	117	1.0	0.95	610.349074	69.802693	0.918654	
97	0.3	0.80	8.895009	3.360213		101	0.3	1.00	635.723392	7.717824	0.991002	
84	0.1	1.00	9.030159	0.789759	0.938199	134	3.0	0.95	645.080313	358.647555	0.581793	

67

66

0.03

0.03

IC 50

A\_max

Lambda Alpha MSE Val MSE Train

0.158408

0.159082

0.047683

0.044421

1.00

0.95

R2

0.813496

0.826257

### Analysis of hyperparameter tuning

- Paper
  - Did not state their hyperparameter
  - Stated they chose ones with smallest MSE

	Lambda	Alpha	MSE Val	MSE Train	R2
135	3.0	1.00	535.081636	317.188125	0.630173
118	1.0	1.00	550.770765	68.105051	0.920636
117	1.0	0.95	610.349074	69.802693	0.918654
101	0.3	1.00	635.723392	7.717824	0.991002
134	3.0	0.95	645.080313	358.647555	0.581793

	Lambda	Alpha	MSE Val	MSE Train	R2
67	0.03	1.00	0.158408	0.047683	0.813496
66	0.03	0.95	0.159082	0.044421	0.826257
65	0.03	0.90	0.160146	0.041204	0.838838
64	0.03	0.85	0.161186	0.037957	0.851542
63	0.03	0.80	0.162848	0.034817	0.863821

#### Activity Area

	Lambda	Alpha	MSE Val	MSE Train	R2
101	0.3	1.00	8.542118	4.143462	0.675630
100	0.3	0.95	8.604842	3.955840	0.690318
99	0.3	0.90	8.668106	3.755339	0.706022
98	0.3	0.85	8.760968	3.548933	0.722189
97	0.3	0.80	8.895009	3.360213	0.736963
84	0.1	1.00	9.030159	0.789759	0.938199

A\_max

IC 50

### Bootstrapping for finding significant features

- Generated 200 resampled datasets by sampling train data with replacement
- Each consists of 250 samples, about (1-1/e) or 63% of the training data size
- Solve elastic net for each bootstrap dataset
  - $\circ$  Used the optimal  $\alpha$  and  $\lambda$  from the hyperparameter training
- Generate a matrix of regression coefficients  $\beta$ 
  - Each row, k, represents the solution for one bootstrap dataset
  - Each column, j, is the weight on that feature
- Calculate percentage of bootstrap datasets inferred as significant for each feature:

$$r_{j} = \sum_{k=1}^{200} \left( 1 \left( \beta_{j,k}^{BS} \right) \right) / 200 \quad \text{1 is the indicator function} \quad 1 \left( x \right) = \begin{cases} 0 \text{ if } x=0, \\ 1 \text{ otherwise.} \end{cases}$$

# Top 10 genes that showed up frequently during the bootstrap

	Feature	Pct Sigf
837	153478_at	0.835
924	29978_at	0.745
646	84102_at	0.535
51	114885_at	0.520
033	388272_at	0.485
794	51619_at	0.445
343	7837_at	0.375
306	81928_at	0.375
637	3569_at	0.365
232	3995_at	0.360
	IC50	)

	Feature	Pct	Sigf
1218	10253_at		1.000
2061	112616_at		0.995
6772	27006_at		0.815
4862	2118_at		0.800
2216	114757_at		0.775
2488	1192_at		0.775
3254	140825_at		0.730
5003	2207_at		0.705
2129	11322_at		0.695
7908	29952_at		0.645

# Top 10 genes that showed up frequently

0.723

0.697

0.445

0.482

0.649

0.492

8.0

0.775

0.775

0.73

0.705

0.695

	during	the bootstrap for Activ	vity Area	
Gene ID	Gene Name	Functi	on Frequency	Ave Weight
10253_at	SPRY2	Regulator of MAPK output	1	0.655
112616_at	CMTM7	Tumor suppressor	0.995	0.728
27006_at	FGF22	Mitogenic and cell survival activities	0.815	0.464

Protective function during oxidative stress

IgE receptor involved in allergic reactions

High rate of progression to squamous cell

Chloride intracellular channel

Regulation of myofibril organization

**RET Signaling** 

carcinoma

2118\_at ETV4

1192\_at CLIC1

140825\_at NEURL2

11322\_at TMC6

2207\_at FCER1G

114757\_at CYGB

# Weights have flipped signs when

0.73

0.995

0.705

Weight

0.655

0.482

0.728

0.649

Frequency

0.980

0.845

N/A

N/A

Weight

-0.328

-0.120

-0.014

-0.008

	compared to the	papers	s top re	atures	
		Our r	nodel	Barretin	ıa et al.
Gene			Ave		Ave

Regulator of MAPK output

Regulation of myofibril

IgE receptor involved in

Tumor suppressor

allergic reactions

organization

Name

SPRY2

NEURL2

CMTM7

FCER1G

**Function Frequency** 

# Differences between our model and the paper

- Log-transformed labels
- SNP and CNV data not included in our model

Results from bootstrapping:

Train MSE: 0.039 – Test MSE: 1.63

### Conclusions

- No correlation was found between global chromatin profiling data has with MEK inhibitor sensitivity
- Gene expression data can be used for prediction of MEK inhibitor's activity area
- Our top bootstrapped feature is the paper's top bootstrapped feature for PD-0325901, but flipped in sign

### Thank you! - Questions?

### References

Gillet, J. P., Varma, S., & Gottesman, M. M. (2013). The clinical relevance of cancer cell lines. Journal of the National Cancer Institute, 105(7), 452-458.

Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., ... \& Reddy, A. (2012). The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature, 483(7391), 603.

Litichevskiy, L., Peckner, R., Abelin, J. G., Asiedu, J. K., Creech, A. L., Davis, J. F., ... \& Jaffe, J. D. (2018). A library of phosphoproteomic and chromatin signatures for characterizing cellular responses to drug perturbations. Cell systems, 6(4), 424-443.

Jaffe, J. D., Wang, Y., Chan, H. M., Zhang, J., Huether, R., Kryukov, G. V., ... \& Stegmeier, F. (2013). Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia. Nature genetics, 45(11), 1386–1391. doi:10.1038/ng.2777

Rahman, R., \& Pal, R. (2016, February). Analyzing drug sensitivity prediction based on dose response curve characteristics. In 2016 IEEE-EMBS International Conference on Biomedical and Health Informatics (BHI) (pp. 140-143). IEEE.

Data retrieved from: <a href="https://portals.broadinstitute.org/ccle">https://portals.broadinstitute.org/ccle</a>

https://www.diagenode.com/en/categories/histone-antibodies

 $https://www.researchgate.net/figure/Schematic-representation-of-histone-modifications-The-methylation-sites-are-represented\_fig1\_28\\ 3086163$